The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Lipids constitute the bulk of the dry mass of the brain and have been associated with healthy
function as well as the most common pathological conditions of the brain. Demographic …

Alzheimer's disease (AD) and treatment of the brain in aging require the development of
new biologic drugs, such as recombinant proteins or gene therapies. Biologics are large …

Abstract Parkinson's disease (PD), one of the most common movement and
neurodegenerative disorders, is challenging to treat, largely because the blood-brain barrier …

Brain exposure of systemically administered biotherapeutics is highly restricted by the blood-
brain barrier (BBB). Here, we report the engineering and characterization of a BBB transport …

Effective delivery of protein therapeutics to the central nervous system (CNS) has been
greatly restricted by the blood-brain barrier (BBB). We describe the development of a BBB …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …

CNS disorders are on the rise despite advancements in our understanding of their
pathophysiological mechanisms. A major hurdle to the treatment of these disorders is the …

In this modern era, with the help of various advanced technologies, medical science has
overcome most of the health-related issues successfully. Though, some diseases still remain …